Search Results for: f
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
June 16, 2025 08:30 ET Inclusion reflects continued growth and momentum in the company’s mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes Read More »
Actuate Therapeutics Investor Event at ASCO to Discuss Elraglusib Phase 2 Topline Data in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
DATE: May 31, 2025TIME: 6:30 PM CDTLOCATION: Marriott Marquis Chicago, 2121 S Prairie Ave, Chicago, IL 60616 ACCESS THE REPLAY > DOWNLOAD THE TRANSCRIPT >
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
April 17, 2025 08:00 ET CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that data on elraglusib